UK markets close in 1 hour 14 minutes

Atara Biotherapeutics, Inc. (ATRA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.71000.0000 (0.00%)
As of 10:15AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 85.50M
Enterprise value 95.49M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.35
Price/book (mrq)N/A
Enterprise value/revenue 2.75
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.70
52-week change 3-65.87%
S&P500 52-week change 328.04%
52-week high 32.5350
52-week low 30.1990
50-day moving average 30.6753
200-day moving average 30.9646

Share statistics

Avg vol (3-month) 31.66M
Avg vol (10-day) 31.67M
Shares outstanding 5120.42M
Implied shares outstanding 6120.42M
Float 892.6M
% held by insiders 12.77%
% held by institutions 170.84%
Shares short (30 Apr 2024) 411.88M
Short ratio (30 Apr 2024) 411.52
Short % of float (30 Apr 2024) 410.01%
Short % of shares outstanding (30 Apr 2024) 49.86%
Shares short (prior month 28 Mar 2024) 411.23M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-96.85%

Management effectiveness

Return on assets (ttm)-59.06%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)34.7M
Revenue per share (ttm)0.30
Quarterly revenue growth (yoy)2,131.40%
Gross profit (ttm)N/A
EBITDA -215.79M
Net income avi to common (ttm)-233.11M
Diluted EPS (ttm)-2.1200
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)46.24M
Total cash per share (mrq)0.38
Total debt (mrq)56.23M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.59
Book value per share (mrq)-0.82

Cash flow statement

Operating cash flow (ttm)-184.16M
Levered free cash flow (ttm)-25.14M